Vassiliki Papadimitrakopoulou, MD of MD Anderson Cancer Center discusses turning cold tumors into hot tumors using agents that address immune therapy resistance. Some of the emerging targets for this type of therapies are intratumoral injection with TLR-9 agonist or sting agonist that are currently explored in combination with checkpoint inhibitors in melanoma . There are also new studies exploring the same combinations in lung cancer.
Turning Cold Tumors into Hot Tumors Using Immune Therapy Resistance
